BeautyHealth (NASDAQ:SKIN) exceeded Q4 revenue expectations but experienced a 13.7% sales decline. Despite a disappointing revenue guidance for the next quarter, its Hydrafacial product remains popular in the beauty health sector.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay